Similarly, in GIST-100, patients clinically considered at low/intermediate risk with PTEN heterozygous loss had reduced DFS and DMFS (mDMFS, 18.05 months; 95% CI, 5.91 to NR) than those with PTEN normal status (mDMFS, NR; 95% CI, 75.14 to NR; P < .001; Fig 3C). The gene discussed is PTEN; the disease is gastrointestinal stromal tumor.